Monalizumab
- Generic Name
- Monalizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1228763-95-8
- Unique Ingredient Identifier
- 3ZXZ2V0588
- Background
Monalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.
- Associated Conditions
- -
- Associated Therapies
- -
A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- John Sfakianos
- Target Recruit Count
- 60
- Registration Number
- NCT06503614
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Hirva Mamdani
- Target Recruit Count
- 38
- Registration Number
- NCT05903092
- Locations
- 🇺🇸
Karmanos Cancer Center (Wayne State University), Detroit, Michigan, United States
🇺🇸University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 999
- Registration Number
- NCT05221840
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 630
- Registration Number
- NCT05061550
- Locations
- 🇹🇷
Research Site, Izmir, Turkey
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 370
- Registration Number
- NCT04590963
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 19
- Registration Number
- NCT04333914
- Locations
- 🇫🇷
AP-HP Hôpital Bichat Claude Bernard, Paris, France
🇫🇷GH Diaconesses Croix Saint Simon, Paris, France
🇫🇷Institut Gustave Roussy, Villejuif, France
Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial
- First Posted Date
- 2020-03-13
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT04307329
- Locations
- 🇳🇱
NKI-AVL, Amsterdam, Netherlands
Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
- Conditions
- Interventions
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT03801902
- Locations
- 🇺🇸
MD Anderson in The Woodlands, Conroe, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson West Houston, Houston, Texas, United States
Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA
- First Posted Date
- 2017-10-12
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Jules Bordet Institute
- Registration Number
- NCT03307941
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Institut Paoli-Calmettes
- Target Recruit Count
- 18
- Registration Number
- NCT02921685
- Locations
- 🇫🇷
Institut Paoli Calmettes, Marseille, Bouches Du Rhônes, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.